Advertisement
UK markets open in 3 hours 7 minutes
  • NIKKEI 225

    38,059.84
    +431.36 (+1.15%)
     
  • HANG SENG

    17,584.63
    +300.09 (+1.74%)
     
  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     
  • GOLD FUTURES

    2,345.00
    +2.50 (+0.11%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,545.53
    +81.34 (+0.16%)
     
  • CMC Crypto 200

    1,390.19
    +7.62 (+0.55%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Invitation to Idorsia's half year financial results 2022 webcast and conference call

Idorsia Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd

Idorsia will publish its half year financial results 2022 on Tuesday July 26, 2022, at 07:00 CEST.

An investor conference call and webcast will be held to discuss the results on the same day.

Date:         Tuesday, July 26, 2022

Time:         14:00 CEST / 13:00 BST / 08:00 EDT

The call will start with presentations by senior management, followed by a Q&A session.

To support your preparations, the consensus estimates can be found under: www.idorsia.com/consensus-estimate.

Dial-in procedure:
      1)   Participants are required to register in advance of the conference (link already open for registration) using the link provided below. Upon registration, each participant will be provided with participant dial in numbers, and a unique personal PIN.
      2)   In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the Call Me feature instead of dialing the nearest dial in number.

ADVERTISEMENT

Online Registration: LINK

Webcast: Participants should go to the Idorsia website www.idorsia.com 10-15 minutes before the conference is due to start.

Replay: A replay of the investor webcast will be available through www.idorsia.com approximately 60 minutes after the call has ended.


Kind regards,

Andrew C. Weiss
Head of Investor Relations and Corporate Communications

Attachment